Compare Rockwell Automation (ROK) vs TG Therapeutics Inc (TGTX) Price & Performance

Rockwell Automation (ROK) trades at $432.59, down 2.11% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 49.09% gross margin and 34.47% ROE, though net income declined to $869M in 2025. Recent news highlights leadership in industrial automation, including partnerships in AI cybersecurity and robotic platforms, supporting positive long-term demand trends.

The stock presents a mixed outlook: analyst consensus targets $489.89 (13% upside) with a majority Hold rating, but high valuation ratios (P/E 40.65) and recent earnings misses pose risks. Key opportunities include automation tailwinds from data centers and labor shortages, while execution on revenue growth and margin stabilization remains critical for shareholder value.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.